Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic, Safety, and Immunogenicity Similarity Between 9MW4113 and Dupixent in Healthy Participants
NCT07791342Phase 1Active, not recruiting
- Sponsor
- Mabwell
- Start
- Apr 2026
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 9MW4113 in atopic dermatitis (AD) (2 arms), sponsored by Mabwell. Primary endpoint: Pharmacokinetics Endpoint. Started Apr 2026; status: active, not recruiting.
02
Drugs
9MW4113
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07791342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07791342.